Eli Lilly and Co. tapped into Amazon Web Services to crunch a vast chunk of data associated with the development of a new drug. Its research time collapsed from three months to two hours, a huge advantage in the highly competitive pharmaceutical business.
The company repatriated the data over a secure line that connected end-to-end with Amazon. But the firm found there was no way to prove that all its data had left the Amazon cloud. It had to take Amazon’s word for it, which raised security concerns.
Read the full story here: